Clovis Oncology Inc (CLVS) : Simplex Trading added new position in Clovis Oncology Inc during the most recent quarter end. The investment management firm now holds 24,883 shares of Clovis Oncology Inc which is valued at $731,809 , the company said in a statement filed on Oct 7, 2016 with the SEC.Clovis Oncology Inc makes up approximately 0.10% of Simplex Trading’s portfolio.
Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa boosted its stake in CLVS in the latest quarter, The investment management firm added 1,405 additional shares and now holds a total of 2,639 shares of Clovis Oncology Inc which is valued at $98,382.
Clovis Oncology Inc closed down -6.36 points or -17.78% at $29.41 with 1,95,37,046 shares getting traded on Friday. Post opening the session at $27.56, the shares hit an intraday low of $25.5 and an intraday high of $31.49 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Clovis Oncology Inc reported $-2.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 8, 2016. Analyst had a consensus of $-2.11.During the same quarter in the previous year, the company posted $-2.10 EPS.
Many Wall Street Analysts have commented on Clovis Oncology Inc. Clovis Oncology Inc was Upgraded by Credit Suisse to ” Outperform” on Sep 21, 2016. Company shares were Reiterated by Stifel on Sep 21, 2016 to “Buy”, Firm has raised the Price Target to $ 45 from a previous price target of $30 .Company shares were Reiterated by Mizuho on Aug 24, 2016 to “Neutral”, Firm has raised the Price Target to $ 23 from a previous price target of $15 .
Clovis Oncology Inc. (Clovis) is a biopharmaceutical company focused on acquiring developing and commercializing anti-cancer agents in the United States Europe and additional international markets. The Company is developing three product candidates: Rociletinib Rucaparib and Lucitanib. Rociletinib an oral epidermal growth factor receptor (EGFR) is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib an oral inhibitor of poly (ADP-ribose) polymerase (PARP) is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3) vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.